e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Animal models of lung injury: useful or not?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Ageing Smad3 KO mice develop emphysema and are resistant to Transforming growth factor-β1 (TGF-β1) mediated pulmonary fibrosis
P. Bonniaud, M. Kolb, T. Galt, J. Robertson, C. Robbins, A. B. Roberts, P. J. Margetts, J. Gauldie (Hamilton, Canada; Dijon, France; Wurzburg, Germany; Bethesda)
Source:
Annual Congress 2003 - Animal models of lung injury: useful or not?
Session:
Animal models of lung injury: useful or not?
Session type:
Oral Presentation
Number:
3327
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Bonniaud, M. Kolb, T. Galt, J. Robertson, C. Robbins, A. B. Roberts, P. J. Margetts, J. Gauldie (Hamilton, Canada; Dijon, France; Wurzburg, Germany; Bethesda). Ageing Smad3 KO mice develop emphysema and are resistant to Transforming growth factor-β1 (TGF-β1) mediated pulmonary fibrosis. Eur Respir J 2003; 22: Suppl. 45, 3327
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Connective tissue growth factor (CTGF) induces lung fibrosis in otherwise fibrosis-resistant Balb/c mouse in a bleomycin model
Source: Eur Respir J 2004; 24: Suppl. 48, 104s
Year: 2004
Wnt11 inhibits effects of transforming growth factor-beta1 (TGFbeta1) on lung epithelial phenotype
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Epidermal growth factor receptor (EGFR) activation is required for TGFbeta1-induced epithelial-mesenchymal transition (EMT) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Altered expression of the Smad signalling pathway: implications for COPD pathogenesis
Source: Eur Respir J 2006; 28: 533-541
Year: 2006
17(R)-resolvinD1 mediates a pathway involving the transcription factor c-Fos to reduce bleomycin-induced pulmonary fibrosis in mice.
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Development of pulmonary fibrosis in conditional Nedd4-2 deficient mice
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Amplified virus infection in a transforming growth factor-beta (TGFB) transgenic mouse model of inflammatory lung disease
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Disruption of Nrf2 enhances susceptibility to pulmonary fibrosis induced by bleomycin in mice
Source: Annual Congress 2011 - The ageing pulmonary interstitium
Year: 2011
The contribution of transforming growth factor-β and epidermal growth factor signalling to airway remodelling in chronic asthma
Source: Eur Respir J 2006; 27: 208-229
Year: 2006
Pleural fibrosis induced by transforming growth factor (TGF)-β1 gene transfer
Source: Eur Respir J 2005; 26: Suppl. 49, 100s
Year: 2005
Calcium-sensing receptor (CaSR) drives lung ECM remodelling and fibrosis in murine asthma models and in ageing mice
Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets
Year: 2019
A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Late Breaking Abstract - Il24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing the m2 program in macrophages
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019
Haemophilus influenzae
(NTHi) up-regulates acute inflammation in human lung tissue and causes downregulation of transforming growth factor-beta (TGF-beta) – A possible role of NTHi in remodeling processes in human lung tissue
Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease
Year: 2010
Modulation of fibroblast phenotype in idiopathic pulmonary fibrosis: Role of Nrf2
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
Transforming growth factor-? gene polymorphisms in different phenotypes of sarcoidosis
Source: Eur Respir J 2011; 37: 169-175
Year: 2011
Transforming growth factor-β type II receptor in pulmonary arteries of patients with very severe COPD
Source: Eur Respir J 2006; 28: 556-562
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept